# OnCo record nct06188520 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06188520/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06188520", "NCT06188520" ;
  schema:name "A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With "@en ;
  schema:alternateName "CYCAD-1"@en ;
  schema:description "A phase 1/2 trial of Camizestrant, Ribociclib, Palbociclib in ovarian cancer, run by AstraZeneca, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06188520/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06188520> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2023-12-05" ;
  onco:cancers <https://onco.cc/cancers/ovarian/> ;
  onco:drugs <https://onco.cc/drugs/camizestrant/>, <https://onco.cc/drugs/ribociclib/>, <https://onco.cc/drugs/palbociclib/>, <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/drugs/azd8421/> ;
  onco:companies <https://onco.cc/companies/astrazeneca/> .